{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:40:39Z","timestamp":1790775639137,"version":"4.1.0"},"reference-count":20,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The activities of ceftolozane-tazobactam and comparator agents against organisms deemed to be the cause of pneumonia among patients hospitalized in the United States during 2013 to 2015 were evaluated. Organisms included 1,576\n            <jats:named-content content-type=\"genus-species\">Pseudomonas aeruginosa<\/jats:named-content>\n            and 2,362\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            isolates susceptibility tested using reference broth microdilution methods. Ceftolozane-tazobactam, cefepime, ceftazidime, meropenem, and piperacillin-tazobactam inhibited 96.3%, 84.8%, 83.5%, 80.0%, and 78.6%, respectively, of the\n            <jats:named-content content-type=\"genus-species\">P. aeruginosa<\/jats:named-content>\n            isolates. Ceftolozane-tazobactam inhibited 77.5 to 85.1% of isolates nonsusceptible to antipseudomonal \u03b2-lactams and 86.6% and 71.0% of the 372 (23.6% overall) multidrug- and 155 (9.8%) extensively drug-resistant isolates tested. The activity of this combination was greater than those of other \u03b2-lactams evaluated against\n            <jats:named-content content-type=\"genus-species\">P. aeruginosa<\/jats:named-content>\n            groups across all U.S. census divisions. Ceftolozane-tazobactam was active against 90.6% of the\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            , being less active than only meropenem (95.6% susceptible) among the \u03b2-lactams evaluated. Against 145\n            <jats:named-content content-type=\"genus-species\">Escherichia coli<\/jats:named-content>\n            and\n            <jats:named-content content-type=\"genus-species\">Klebsiella pneumoniae<\/jats:named-content>\n            isolates carrying extended-spectrum-\u03b2-lactamase (ESBL)-encoding genes without carbapenemases, ceftolozane-tazobactam inhibited 82.8% of these isolates and was more active than cefepime and piperacillin-tazobactam (15.2% and 74.3% susceptible, respectively). ESBL genes included in this analysis were mainly\n            <jats:italic>bla<\/jats:italic>\n            <jats:sub>CTX-M-15<\/jats:sub>\n            -like (89 isolates) and\n            <jats:italic>bla<\/jats:italic>\n            <jats:sub>CTX-M-14<\/jats:sub>\n            -like (22) genes but also\n            <jats:italic>bla<\/jats:italic>\n            <jats:sub>SHV<\/jats:sub>\n            (31) and\n            <jats:italic>bla<\/jats:italic>\n            <jats:sub>TEM<\/jats:sub>\n            (3). Ceftolozane-tazobactam also displayed activity (84.6% susceptible) against 13 isolates harboring acquired AmpC genes. All \u03b2-lactams displayed limited activity against\n            <jats:italic>bla<\/jats:italic>\n            <jats:sub>KPC<\/jats:sub>\n            -carrying isolates. Ceftolozane-tazobactam was the most active \u03b2-lactam tested against\n            <jats:named-content content-type=\"genus-species\">P. aeruginosa<\/jats:named-content>\n            isolates from isolates that were the probable cause of pneumonia and displayed\n            <jats:italic>in vitro<\/jats:italic>\n            activity against\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            , including isolates resistant to cephalosporins and carrying ESBL genes.\n          <\/jats:p>","DOI":"10.1128\/aac.02125-17","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T13:36:08Z","timestamp":1513690568000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":44,"title":["Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015"],"prefix":"10.1128","volume":"62","author":[{"given":"Mariana","family":"Castanheira","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard R.","family":"Duncan","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dee","family":"Shortridge","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2011.599320"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-014-3564-5"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-016-2703-z"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1017\/ice.2016.174"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/1040841X.2013.875515"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir790"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir793"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix014"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2017.04.001"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkw374"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw243"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/595011"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02252-12"},{"key":"e_1_3_2_15_2","volume-title":"M07-A10","author":"CLSI","year":"2015","unstructured":"CLSI. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 10th ed. M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"10"},{"key":"e_1_3_2_16_2","volume-title":"M100-S26","author":"CLSI","year":"2016","unstructured":"CLSI. 2016. Performance standards for antimicrobial susceptibility testing: 26th informational supplement. M100-S26. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_17_2","unstructured":"EUCAST. 2016. Breakpoint tables for interpretation of MICs and zone diameters version 6.0 1 January 2016. http:\/\/www.eucast.org\/clinical_breakpoints\/. Accessed January 2016."},{"key":"e_1_3_2_18_2","volume-title":"Tygacil package insert","author":"Wyeth Pharmaceuticals","year":"2016","unstructured":"Wyeth Pharmaceuticals. 2016. Tygacil package insert. Wyeth Pharmaceuticals, Philadelphia, PA. http:\/\/www.tygacil.com. Accessed 23 February 2017."},{"key":"e_1_3_2_19_2","volume-title":"M100-S25","author":"CLSI","year":"2015","unstructured":"CLSI. 2015. Performance standards for antimicrobial susceptibility testing: 25th informational supplement. M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01802-13"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02125-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02125-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:03:41Z","timestamp":1645477421000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02125-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1128\/AAC.02125-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.02125-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"2017-10-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02125-17"}}